Aktie 1752 NANG KUANG PHARMACEUTICAL CO., LTD.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Nang Kuang Pharmaceutical Co., Ltd.

Aktien

1752

TW0001752004

1752

Schlusskurs Taiwan S.E.
Andere Börsenplätze
 00:00:00 10.05.2024 		% 5 Tage % 1. Jan.
45,45 TWD +1,56 % Intraday Chart für Nang Kuang Pharmaceutical Co., Ltd. +1,91 % -14,73 %
08.05. Nang Kuang Pharmaceutical Co., Ltd. meldet Ergebnis für das erste Quartal bis zum 31. März 2024 CI
26.03. Nang Kuang Pharmaceutical Co. Ltd. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Nang Kuang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Nang Kuang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Nang Kuang Pharmaceutical Co., Ltd. Announces Changes in Chief Internal Auditor
Nang Kuang Pharmaceutical Co., Ltd. Appoints Pen-Sung Chen as Corporate Governance Officer
Nang Kuang Pharmaceutical Co., Ltd. Announces Resignation of Wen-Yung Tsai as Spokesperson, Financial Officer, Accounting Officer and Corporate Governance Officer
Nang Kuang Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nang Kuang Pharmaceutical Co., Ltd.(TWSE:1752) added to S&P Global BMI Index
Nang Kuang Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Nang Kuang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Nang Kuang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
Nang Kuang Pharmaceutical Co., Ltd. Appoints Wen-Yung Tsai as Corporate Governance Officer
Nang Kuang Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Nang Kuang Pharmaceutical : Announcement of the consolidated financial report for the 2nd quarter of 2022 approved by the board of directors
Nang Kuang Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
Nang Kuang Pharmaceutical : has received final U.S.FDA approval for its ANDA.
Nang Kuang Pharmaceutical Co., Ltd. Receives Final U.S. FDA Approval for Its ANDA
Nang Kuang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
Nang Kuang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
Nang Kuang Pharmaceutical Co., Ltd.(TWSE:1752) added to Taiwan TAIEX Index
Nang Kuang Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. 1752 Aktie
  4. Nachrichten Nang Kuang Pharmaceutical Co., Ltd.
  5. Andere Sprachen